Investor presentation H1/FY26
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported strong H1FY26 results with consolidated revenue of INR 280.7 crore, up 57% YoY, and EBITDA of INR 69.1 crore, up 173% YoY. Profit after tax surged 664% to INR 39.6 crore, translating to EPS of INR 13.87. The Human Nutrition segment drove growth with volumes up 74% and the German toll manufacturing subsidiary revenue rising 194% to INR 34.3 crore. EBITDA margin held steady at 25.9%, debt-to-equity improved to 0.27x, interest coverage rose sharply to 10.18x, and free cash flow turned positive at INR 26 crore. Key strategic moves included receiving an Indian patent for plant-based Vitamin D3 manufacturing and divesting the Environment Division to a wholly owned subsidiary for INR 19 crore.
Strong revenue and profit growth, sustained margins, and improved cash generation signal healthy momentum for shareholders. Lower leverage and active portfolio reshaping (divestiture plus new patent) should support valuation, though some growth was aided by a non-recurring insurance claim and inventory provision reversals.